Improving resectability of hepatic colorectal metastases: expert consensus statement, Ann Surg Oncol, vol.13, issue.10, pp.1271-80, 2006. ,
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity, Arthritis Rheum, vol.40, issue.12, pp.2217-2242, 1997. ,
Kirsten ras mutations in patients with colorectal cancer: the « RASCAL II » study, Br J Cancer, vol.85, issue.5, pp.692-698, 2001. ,
, Association canadienne du cancer colorectal. Comprendre le cancer coloreactal
,
Quantitative Cell-Based Reporter Gene Assays Using Droplet-Based Microfluidics, Chem Biol, vol.17, issue.5, pp.528-564, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02148764
Tumor markers: value and limitations in the management of cancer patients, Cancer Treat Rev, vol.12, issue.3, pp.163-207, 1985. ,
Molecular Detection Of TP53, KiRas And P16ink4a Promoter Methylation In Plasma Of Patient s With Colorectal Cancer And Its Association With Prognosis ,
, Prospective Study. Ann Oncol, vol.17, issue.7, pp.84-90, 2006.
Therapeutic Strategy In Unresectable Metastatic Colorectal Cancer: An Updated Review, Ther Adv Med Oncol, vol.7, issue.3, 2015. ,
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, vol.14, issue.1, pp.29-37, 2013. ,
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014. ,
Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view, Bull Cancer, vol.96, pp.15-22, 2009. ,
, ABC of colorectal cancer: Epidemiology. BMJ, vol.321, issue.7264, pp.805-813, 2000.
Circulating cell-free DNA: an up-coming molecular marker in exercise physiology, Sports Med, vol.42, issue.7, pp.565-86, 2012. ,
Sandrine Faivre. PI3K / AKT / Mtor Signalling Pathway. Cancéro Dig ,
, Centers for Disease Control and Prevention & National Cancer Institute; Cancer Statistics Working Group
Department of Health and Human Services ,
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer, Oncology, vol.87, issue.3, pp.148-58, 2014. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011. ,
Validation of analytic methods for biomarkers used in drug development, Clin Cancer Res, vol.14, pp.5967-76, 2008. ,
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study ,
, BMJ, vol.342, p.7401, 2011.
The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells, Immunology, vol.115, issue.1, pp.55-62, 2005. ,
Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine, Methods, vol.59, issue.1, pp.101-108, 2013. ,
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med, vol.368, issue.13, pp.1199-209, 2013. ,
Clinical biomarkers in oncology: focus on colorectal cancer, Mol Diagn Ther, vol.13, issue.2, pp.103-117, 2009. ,
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, vol.11, issue.8, pp.753-62, 2010. ,
Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, issue.5, pp.815-838, 2013. ,
Place de l'ADN tumoral circulant dans la prise en charge des patients atteints d'une tumeur pulmonaire : impact pronostique et suivi dynamique de l'évolution des altérations génétiques au cours du traitement. Mémoire de l'École Pratique des Hautes Études, p.124, 2017. ,
Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci USA, vol.102, issue.45, pp.16368-73, 2005. ,
Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, issue.9, pp.985-90, 2008. ,
DOI : 10.1038/nm.1789
URL : http://europepmc.org/articles/pmc2820391?pdf=render
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat Rev Cancer, 2017. ,
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations, Proc Natl Acad Sci USA, vol.100, issue.15, pp.8817-8839, 2003. ,
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Ann Oncol, vol.25, issue.7, pp.1346-55, 2014. ,
Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability, Cancer Res, vol.62, issue.9, pp.2447-54, 2002. ,
,
, Aberrations Confer Poor Prognosis In Human Colorectal Cancer, J Clin Oncol, vol.19, issue.2, pp.299-304, 2001.
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, vol.25, issue.13, pp.1670-1676, 2007. ,
Circulating nucleic acids (CNAs) and cancer-a survey, Biochim Biophys Acta, vol.1775, issue.1, pp.181-232, 2007. ,
Etude de la structure et de l'origine des ADN circulants : application à la mise au point d'un test de détection des mutations KRAS et BRAF dans le cancer colorectal. Université de Montpellier 2, Sciences Chimiques et Biologiques pour la Santé, p.123, 2012. ,
, Physical Activity, and the Prevention of Cancer. World Cancer Research Fund and American Institute for Cancer Research: A Global Perspective, 2007.
, Institut National Du Cancer .Les cancers en France en 2014-L'essentiel des faits et chiffres
,
Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders, Autoimmun Rev, vol.2, issue.1, pp.50-55, 2003. ,
, Nucleosomes In Serum Of Patients With Early Cerebral Stroke. Cerebrovasc Dis, vol.21, issue.1, pp.32-39, 2006.
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, vol.25, issue.12, pp.1539-1583, 2007. ,
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance, Mutat Res, vol.635, issue.2-3, pp.105-122, 2007. ,
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line, J Clin Oncol, vol.23, issue.36, pp.9441-9443, 2005. ,
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, vol.381, issue.9863, pp.303-315, 2013. ,
Marqueurs de réponse aux thérapies ciblées et personnalisation thérapeutique dans les cancers colorectaux métastatiques, p.152, 2014. ,
,
, Nat Meth, vol.8, issue.8, pp.649-51, 2011.
, Apoptosis In Serum Of Patients With Solid Tumours. Anticancer Res, vol.19, issue.4A, pp.2721-2725, 1999.
Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array, Journal of Translational Medicine, vol.12, p.147, 2014. ,
, Institut National Du Cancer .Les cancers en France en 2014-L'essentiel des faits et chiffres
,
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis, Nature, 1993. ,
Descriptive epidemiology of colorectal cancer in the United States, Cancer, vol.107, issue.5, pp.1103-1114, 1998. ,
DNA Fragments In The Blood Plasma Of Cancer Patients: Quantitations And Evidence For Their Origin From Apoptotic And Necrotic Cells, Cancer Res, vol.61, issue.4, pp.1659-65, 2001. ,
Molecular Mechanisms of Colorectal Carcinogenesis. In Molecular Pathogenesis of Colorectal Cancer, pp.25-65, 2013. ,
Global cancer statistics, Cancer Journal for Clinicians, vol.61, issue.2, pp.69-90, 2011. ,
Lengthening And Shortening Of Plasma DNA In Hepatocellular Carcinoma Patients, Proc Natl Acad Sci USA, vol.112, issue.11, pp.1317-1342, 2015. ,
The Fundamental Role Of Epigenetic Events In Cancer, Nat Rev Genet, 2002. ,
Prevalence of adenomas among young individuals at average risk for colorectal cancer, Am J Gastroenterol, 2005. ,
Cell-Free DNA In The Blood As A Solid Tumor Biomarker-A Critical Appraisal Of The Literature, Clin Chim Acta, vol.411, pp.1611-1635, 2010. ,
Quantitative Detection Of EGFR Mutations In Circulating Tumor DNA Derived From Lung Adenocarcinomas. Clinical Cancer, pp.11-1712, 2011. ,
Dual-Specificity MAP Kinase Phosphatases (Mkps) And Cancer, Cancer Metastasis Rev, vol.27, issue.2, pp.253-61, 2008. ,
DOI : 10.1007/s10555-008-9123-1
,
, Extracellular circulating nucleic acids in human plasma in health and disease, Nucleosides Nucleotides Nucleic Acids, vol.23, issue.6-7, pp.879-83, 2004.
Circulating free tumor DNA and colorectal cancer ,
DOI : 10.1016/j.gcb.2009.04.015
URL : https://hal.archives-ouvertes.fr/hal-00618040
, Gastroenterol Clin Biol, vol.34, issue.12, pp.662-81, 2010.
Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977. ,
La voie de signalisation RAS/MAPK RAS/MAPK signaling pathway. Cancéro dig, vol.2, pp.1-2010 ,
Oncogenic mutations as predictive factors in colorectal cancer, Oncogene, vol.29, issue.21, pp.3033-3076, 2010. ,
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, issue.8, pp.3992-3997, 2006. ,
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, vol.26, issue.3, pp.374-383, 2008. ,
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival, PLoS ONE, vol.6, issue.11, p.27419, 2011. ,
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC, Nat Rev Clin Oncol, vol.6, issue.6, pp.352-66, 2009. ,
Presence of fetal DNA in maternal plasma and serum, Lancet, vol.350, issue.9076, pp.485-492, 1997. ,
Rapid clearance of fetal DNA from maternal plasma, Am J Hum Genet, vol.64, issue.1, pp.218-242, 1999. ,
Ras family genes: An interesting link between cell cycle and cancer, J Cell Physiol, vol.192, issue.2, pp.125-155, 2002. ,
DOI : 10.1002/jcp.10109
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells, N Engl J Med, vol.359, issue.4, pp.366-77, 2008. ,
Les Acides Nucléiques Du Plasma Sanguin Chez L'homme, C R Seances Soc Biol Fil, vol.142, issue.3-4, pp.241-244, 1948. ,
Molecular origins of cancer: Molecular basis of colorectal cancer, N Engl J Med, vol.361, issue.25, pp.2449-60, 2009. ,
CEA Monitoring in Colorectal Cancer | Cancer Network, 2016. ,
Epidermal growth factor receptor targeting in cancer, Semin Oncol, 2006. ,
, Biomarqueurs Moléculaires en Oncologie, p.175, 2014.
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to antiEGFR treatment, Ann Oncol, vol.26, issue.4, pp.731-737, 2015. ,
Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load, Transl Oncol, vol.6, issue.3, pp.319-347, 2013. ,
DOI : 10.1593/tlo.12445
URL : https://hal.archives-ouvertes.fr/hal-00872683
Circulating Tumor-Derived DNA Is Shorter Than Somatic DNA In Plasma ,
, Proc Natl Acad Sci USA, vol.112, issue.11, pp.3178-3187, 2015.
Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum, J Clin Oncol, vol.24, issue.26, pp.4270-4276, 2006. ,
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, issue.5, pp.548-54, 2014. ,
DOI : 10.1038/nm.3519
URL : http://europepmc.org/articles/pmc4016134?pdf=render
Cell-free DNA Analysis for Noninvasive Examination of Trisomy, N Engl J Med, vol.372, issue.17, pp.1589-97, 2015. ,
Principles & practice of oncology (6th edn), vol.75, pp.567-567, 2001. ,
PCR Digitale En Micro-Compartiments-I. Détection Sensible De Séquences D'acides Nucléiques Rares, Med Sci, vol.31, issue.1, pp.84-92, 2015. ,
DOI : 10.1051/medsci/20153101017
URL : https://hal.archives-ouvertes.fr/hal-01140226
Quantitative And Sensitive Detection Of Rare Mutations Using Droplet-Based Microfluidics, Lab Chip, vol.11, issue.13, pp.2156-66, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02148770
Translocation And Destination Of Extracellular Occurring DNA-A New Paradigm In Genetic Behaviour, Clin Chim Acta, vol.412, pp.806-817, 2011. ,
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, vol.12, issue.3, pp.145-51, 2013. ,
Characterization and localization of cisdiamminedichloro-platinum(II) adducts on a purified oligonucleotide containing the codons 12 and 13 of H-ras proto-oncogene, Nucleic Acids Res, vol.20, issue.24, pp.6473-6482, 1992. ,
The chromosomal instability pathway in colon cancer, Gastroenterology, 2010. ,
Quel Avenir Pour L'adn Tumoral Circulant ? État Des Lieux Et Perspectives Dans Les Cancers Colorectaux, Pulmonaires Non A Petites Cellules Et Pancréatiques, Bull Cancer, vol.103, issue.1, pp.55-65, 2016. ,
PIK3CA Mutations Are Not A Major Determinant Of Resistance To The Epidermal Growth Factor Receptor Inhibitor Cetuximab In Metastatic Colorectal Cancer, Clin Cancer Res, vol.15, issue.9, pp.3184-3192, 2009. ,
, Alcohol and cancer. Alcohol Alcohol, vol.39, issue.3, pp.155-65, 2004.
PIK3CA Mutations In Colorectal Cancer Are Associated With Clinical Resistance To EGFR-Targeted Monoclonal Antibodies, Cancer Res, vol.69, issue.5, pp.1851-1858, 2009. ,
Detection Of Ultra-Rare Mutations By Next-Generation Sequencing, Proc Natl Acad Sci USA, vol.109, issue.36, pp.14508-14521, 2012. ,
Methylation Of Endogenous Human Retroelements In Health And Disease, Curr Top Microbiol Immunol, vol.310, pp.211-50, 2006. ,
Cell-Free Nucleic Acids As Biomarkers In Cancer Patients, Nat Rev Cancer, vol.11, issue.6, pp.426-463, 2011. ,
Cancer statistics, Cancer Journal for Clinicians, vol.65, issue.1, pp.5-29, 2015. ,
DOI : 10.3322/caac.21332
Autocrine, paracrine and juxtacrine signaling by EGFR ligands, Cell Signal, vol.17, issue.10, pp.1183-93, 2005. ,
DOI : 10.1016/j.cellsig.2005.03.026
Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome, J Mol Diagn, vol.10, issue.4, pp.293-300, 2008. ,
TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer, Cancer, 2010. ,
Soluble Normal And Mutated DNA Sequences From Single-Copy Genes In Human Blood, Cancer Epidemiol Biomarkers Prev ,
Detection Of Mutated KRAS2 Sequences As Tumor Markers In Plasma/Serum Of Patients With Gastrointestinal Cancer, Clin Cancer Res, vol.6, issue.6, pp.2129-2166, 2000. ,
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG), Br J Cancer, vol.94, issue.6, pp.798-805, 2006. ,
Analysis Of Circulating Tumor DNA In Plasma At Diagnosis And During Follow-Up Of Lung Cancer Patients, Cancer Res, 2001. ,
Cell-Free DNA In Healthy Individuals, Noncancerous Disease And Strong Prognostic Value In Colorectal Cancer, Int J Cancer, vol.135, issue.12, pp.2984-91, 2014. ,
Neoplastic Characteristics Of The DNA Found In The Plasma Of Cancer Patients, Oncology, vol.46, issue.5, pp.318-340, 1989. ,
Fate Of DNA Of Bacterial Origin After Its Migration Into Plants, Arch Int Physiol Biochim, vol.74, issue.5, pp.935-942, 1966. ,
Quantitation Of Targets For PCR By Use Of Limiting Dilution, Biotechniques, vol.13, issue.3, pp.444-453, 1992. ,
Man-Made Cell-Like Compartments For Molecular Evolution, Nat Biotech ,
, Droplet Microfluidics. Lab Chip, vol.8, issue.2, pp.198-220, 2008.
Multiplex Picodroplet Digital PCR To Detect KRAS Mutations In Circulating DNA From The Plasma Of Colorectal Cancer Patients ,
, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013.
,
, Circulating DNA And Dnase Activity In Human Blood. Ann N Y Acad Sci, vol.1075, pp.191-197, 2006.
Serum LINE-1 Hypomethylation As A Potential Prognostic Marker For Hepatocellular Carcinoma, Clinica Chimica Acta, vol.379, issue.1-2, pp.127-160, 2007. ,
Clinical Validation Of The Detection Of KRAS And BRAF Mutations From Circulating Tumor DNA, Nat Med, 2014. ,
The Predictive Value Of KRAS, NRAS, BRAF, PIK3CA And PTEN For Anti-EGFR Treatment In Metastatic Colorectal Cancer: A Systematic Review And Meta-Analysis, Acta Oncol, vol.53, issue.7, pp.852-64, 2014. ,
Microsatellite instability in cancer of the proximal colon, Science, vol.260, issue.5109, pp.816-825, 1993. ,
Prognostic Value Of Circulating KRAS2 Gene Mutations In Colorectal Cancer With Distant Metastases, Int J Biol Markers, vol.21, issue.4, pp.223-231, 2006. ,
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study ,
, J Clin Oncol, vol.22, issue.2, pp.229-266, 2004.
Irinotecan in the treatment of colorectal cancer: clinical overview, J Clin Oncol, vol.19, issue.5, pp.1501-1519, 2001. ,
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 2009. ,
Addition Of Aflibercept To Fluorouracil, Leucovorin, And Irinotecan Improves Survival In A Phase III Randomized Trial In Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaliplatin-Based Regimen, J Clin Oncol, vol.30, issue.28, pp.3499-506, 2012. ,
Cetuximab Plus Irinotecan, Fluorouracil, And Leucovorin As First-Line Treatment For Metastatic Colorectal Cancer: Voelkerding KV, Dames S, Durtschi JD. Next Generation Sequencing For Clinical DiagnosticsPrinciples And Application To Targeted Resequencing For Hypertrophic Cardiomyopathy, J Mol Diagn, vol.12, issue.5, pp.539-51, 2010. ,
, Updated Analysis Of Overall Survival According To Tumor KRAS And BRAF Mutation Status, J Clin Oncol, vol.29, issue.15, pp.2011-2020, 2011.
The Differentially Mutational Spectra Of The APC, K-Ras, And P53 Genes In Sporadic Colorectal Cancers From Taiwanese Patients ,
, Hepatogastroenterology, vol.54, issue.80, pp.2259-65, 2007.
Increased Plasma DNA Integrity In Cancer Patients, Cancer Res, vol.63, issue.14, pp.3966-3974, 2003. ,
Diet And Cancer: An Evolving Picture, JAMA, vol.293, issue.2, pp.233-237, 2005. ,
Overview Of The Epidemiology Of Colorectal Cancer, Dis Colon Rectum, 1997. ,
, World Health Organization. Estimation Cancer Incidence Mortality And Prevalence Worlwide, 2012.
,
, World Health Organization. Colorectum Cancer Statistics In India, 2012.
,
Detection Of KRAS Oncogene In Peripheral Blood As A Predictor Of The Response To Cetuximab Plus Chemotherapy In Patients With Metastatic Colorectal Cancer, Clin Cancer Res, vol.15, issue.13, pp.4508-4521, 2009. ,
Cell-Free Plasma DNA During Peritoneal Dialysis And Hemodialysis And In Patients With Chronic Kidney Disease, Ann N Y Acad Sci, vol.1137, pp.296-301, 2008. ,
Multiplex Digital PCR: Breaking The One Target Per Color Barrier Of Quantitative PCR, Lab Chip, vol.11, issue.13, pp.2167-74, 2011. ,
The Struggle To Detect Circulating DNA, Crit Care, vol.10, issue.3, p.142, 2006. ,
Associations Between The Age At Diagnosis And Location Of Colorectal Cancer And The Use Of Alcohol And Tobacco: Implications For Screening, Arch Intern Med, vol.166, issue.6, pp.629-663, 2006. ,
Prognostic And Predictive Factors In Colorectal Cancer, J Clin Pathol, 2008. ,
, La classification du CCR Annexe 2 : Représentation schématique de différents types de PCR digitale Annexe 3 : Les étapes principales de NGS Annexe 4 : Comparaison des technologies de séquençage à haut débit Annexe 5 : Les principales caractéristiques des billes magnétiques, vol.1
, ~ slUff'f (v/'1) in 10 mM Tris with 0.09'b sodium azidc:, pH &.O Recombinant itteptavldu\ covatc:ntly cou pied to silica·bascd bc:ldJ 10 ~
Y~"f°" dw "'°Ptttitt ef '"" #!d!Wl111rl r«M i1tW!f "* Up to 6 pmolcs oligonuclC01idr pcr vL of bf:ad susptnsion N~: ~dlilf (O,PCK'ltv ls "-11/dy "lll'led 10 lflOll'C'Uk, Up IO 0.65119 llooeon,4atrd IM pa l'l d bud-Up .. 1.0"' boolon,4atrd lg0 ,
, · f\u&\Uboe'll Stttptnidin M'9ftdÎC ladl ltt for munfl UK canly. Thry att not fot ust: in dilgnOl.tit prooedu~ Disposai Collrcl and dispose of uK'd N lcri11l 1cto1dlng to 111 applicable ln1rmational. fcdcral, statr, and local rrgulatlons
, Safety Data Sheet Slftt
, Oltl Shttts CSOS) l fC IVlibtlk Of'I Ol,lf wtb litt. Go to www mi, lll:J!O!!.C'M! Md auu "°"' a Wogw: numbtr 11111 tht wMh boL M Product Ordtring Information
,
, Sia.tAOO, vol.1
,
Notice lhe inrofml llon ln lhis document ls suti;ccl Io cha~c whtloul notice arwl should not bt construed as? commltrnc:nt by Milliporc: Corpor1don ("Milliporc1 or an affi liatc:. Ncittlcr Milllport Cotpor1tiOl'I nat 1nv or iu affiliatH 111umc:s rc:,poMlt>Hlty ror ? nv crf ,
, Technlcal Assistanct fol' MCM'C ~fom'l.IÔOf\ mntact tht Milipoft' offitt Mlttll ~ t
, 90 to out web site: at www.millleors tom'offim for up-1<~
, dite wortd'wlde COf\tact in.formation. You ca.n elso vilit the ttth